ArticleCell death discovery2026
KIF14 silencing suppresses cell proliferation and enhances chemosensitivity by modulating 53BP1 nucleocytoplasmic shuttling in non-WNT/non-SHH medulloblastoma.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Medulloblastoma (MB) is the most common malignant pediatric brain tumor. The non-WNT/non-SHH subtypes (Groups 3 and 4) exhibit high genetic heterogeneity and limited therapeutic options. Kinesin family member 14 (KIF14) is selectively expressed during nervous system development. However, its role in non-WNT/non-SHH MB remains poorly understood. In this study, analysis of the GEO database revealed that high KIF14 expression correlates with poor prognosis in patients with non-WNT/non-SHH MB. Silencing KIF14 in MB cells impaired cytokinesis, leading to p53-mediated cell cycle arrest and apoptosis. Mechanistically, KIF14 knockdown disrupted the nucleocytoplasmic shuttling of the p53-binding protein 53BP1, resulting in its nuclear accumulation. This shift inhibited homologous recombination (HR)-mediated repair of DNA double-stranded breaks (DSBs), thereby enhancing cisplatin-induced DNA damage. In vitro experiments and intracranial orthotopic xenograft models confirmed that KIF14 silencing potentiates the antitumor efficacy of cisplatin treatment. Overall, these findings highlight the critical role of KIF14 in promoting cell proliferation and DNA repair in non-WNT/non-SHH MB and suggest that targeting KIF14 may represent a novel therapeutic strategy to enhance the efficacy of DNA-damaging agents in this challenging MB subtype.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.